RESUMEN
Tannic acid (TA) is a phenolic compound that might act directly on osteoblast metabolism. The study was performed to investigate the effects of TA on the proliferation, mineralization, and morphology of human fetal osteoblast cells (hFOB 1.19). The cells were divided into TA-treated, untreated, and pamidronate-treated (control drug) groups. Half maximal effective concentration (EC50 ) values for TA and pamidronate were measured using MTT assay. The EC50 of hFOB 1.19 cells treated with TA was 2.94 M. This concentration was more effective compared to the pamidronate (15.27 M). Cell proliferation assay was performed to compare cell viability from Day 1 until Day 14. The morphology of hFOB 1.19 was observed via inverted microscope and scanning electron microscope. Calcium (Ca) and phosphate (P) were assessed using energy-dispersive X-ray (EDX) analysis. Furthermore, the mineralization of hFOB 1.19 was determined by von Kossa staining (P depositions) and Alizarin Red S staining (Ca depositions). The number of cells treated with TA was significantly higher than the two control groups at Day 10 and Day 14. The morphology of cells treated with TA was uniformly fusiform-shaped with filopodia extensions. Besides, globular-like structures of deposited minerals were observed in the TA-treated group. In line with other findings, EDX spectrum analysis confirmed the presence of Ca and P. The cells treated with TA had significantly higher percentage of both minerals at Day 3 and Day 10 compared to the two control groups. In conclusion, TA enhances cell proliferation and causes cell morphology changes, as well as improved mineralization.
Asunto(s)
Calcificación Fisiológica/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Feto/citología , Osteoblastos/metabolismo , Taninos/farmacología , Calcio/análisis , Diferenciación Celular/efectos de los fármacos , Línea Celular , Supervivencia Celular/efectos de los fármacos , Humanos , Microscopía Electrónica de Rastreo , Osteoblastos/citología , Pamidronato/farmacología , Fosfatos/análisis , Espectrometría por Rayos XRESUMEN
BACKGROUND: The present study investigated the effects of Quercus infectoria (QI) gall extract on the proliferation, alkaline phosphatase (ALP), osteocalcin, and the morphology of a human fetal osteoblast cell line (hFOB 1.19). METHODS: The cells were cultured in Dulbecco's modified eagle medium F12 supplemented with a 10% fetal bovine serum, a 1% penicillin/streptomycin and were treated with QI at various concentrations (0.1 to 99.0 µg/mL) for 72 hours. The levels of ALP and osteocalcin were measured at day 1, 3, 7, 10, and 14 and were compared among the negative control, pamidronate and QI groups. RESULTS: The median effective concentration (EC50) of hFOB 1.19 treated with QI was 10.30 µg/mL. This concentration was more effective compared to the control drug, pamidronate (EC50 at 16.09 µg/mL). The ALP and osteocalcin levels of hFOB 1.19 treated with QI from day 7 and onwards were significantly increased in a time and concentration-dependent manner. Interestingly, from day 7 until day 14, the ALP and osteocalcin levels were highest in the cells treated with QI compared to the other two groups. The morphology of cells treated with QI was uniformly elongated, higher in number and over-confluent. CONCLUSION: After treatment with QI, cell proliferation enhanced and ALP and osteocalcin levels increased.
RESUMEN
Background: The present study investigated the effects of Quercus infectoria (QI) gall extract on the proliferation, alkaline phosphatase (ALP), osteocalcin, and the morphology of a human fetal osteoblast cell line (hFOB 1.19). Methods: The cells were cultured in Dulbecco’s modified eagle medium F12 supplemented with a 10% fetal bovine serum, a 1% penicillin/streptomycin and were treated with QI at various concentrations (0.1 to 99.0 μg/mL) for 72 hours. The levels of ALP and osteocalcin were measured at day 1, 3, 7, 10, and 14 and were compared among the negative control, pamidronate and QI groups. Results: The median effective concentration (EC50) of hFOB 1.19 treated with QI was 10.30 μg/mL. This concentration was more effective compared to the control drug, pamidronate (EC50 at 16.09 μg/mL). The ALP and osteocalcin levels of hFOB 1.19 treated with QI from day 7 and onwards were significantly increased in a time and concentration-dependent manner. Interestingly, from day 7 until day 14, the ALP and osteocalcin levels were highest in the cells treated with QI compared to the other two groups. The morphology of cells treated with QI was uniformly elongated, higher in number and over-confluent. Conclusion: After treatment with QI, cell proliferation enhanced and ALP and osteocalcin levels increased.